icer white paper affordable access to glp-1 obesity medications 2025 How Supply and Demand for Weight Loss Drugs is Playing Out in 2026 GLP‑1 real‑world data for obesity:

GLP-1-S is a synthetic research peptide studied in laboratory settings for its interaction with GLP-1 receptor signaling pathways, metabolic regulation models, and neuroendocrine communication research

Lemme, a supplement brand co-founded by Kourtney Kardashian, has been targeted by a class action lawsuit for its GLP-1 Daily supplement.

Wegovy is a weight loss medication approved by the FDA

The potential risk of age-related macular degeneration with GLP-1 drugs in people with diabetes

Future randomised controlled trials should specifically evaluate the effectiveness of novel AOMs for long-term weight management in older adults with obesity, carefully considering the impact on body composition and functional ability, as well as health economics.